ID   ACE_MOUSE               Reviewed;        1312 AA.
AC   P09470; P22967; Q6GTS2;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   30-AUG-2005, sequence version 3.
DT   03-AUG-2022, entry version 194.
DE   RecName: Full=Angiotensin-converting enzyme {ECO:0000303|PubMed:2545691};
DE            Short=ACE {ECO:0000303|PubMed:2545691};
DE            EC=3.4.15.1 {ECO:0000269|PubMed:16270063};
DE   AltName: Full=Dipeptidyl carboxypeptidase I;
DE   AltName: Full=Kininase II {ECO:0000250|UniProtKB:P12821};
DE   AltName: CD_antigen=CD143;
DE   Contains:
DE     RecName: Full=Angiotensin-converting enzyme, soluble form {ECO:0000250|UniProtKB:P12821};
DE   Flags: Precursor;
GN   Name=Ace {ECO:0000303|PubMed:2545691, ECO:0000312|MGI:MGI:87874};
GN   Synonyms=Dcp1;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SOMATIC).
RX   PubMed=2545691;
RA   Bernstein K.E., Martin B.M., Edwards A.S., Bernstein E.A.;
RT   "Mouse angiotensin-converting enzyme is a protein composed of two
RT   homologous domains.";
RL   J. Biol. Chem. 264:11945-11951(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TESTIS-SPECIFIC), AND PARTIAL
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2164636;
RA   Howard T.E., Shai S.-Y., Langford K.G., Martin B.M., Bernstein K.E.;
RT   "Transcription of testicular angiotensin-converting enzyme (ACE) is
RT   initiated within the 12th intron of the somatic ACE gene.";
RL   Mol. Cell. Biol. 10:4294-4302(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM SOMATIC).
RC   STRAIN=FVB/N; TISSUE=Mammary gland;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RA   Gerhard D.S., Wagner L., Feingold E.A., Shenmen C.M., Grouse L.H.,
RA   Schuler G., Klein S.L., Old S., Rasooly R., Good P., Guyer M., Peck A.M.,
RA   Derge J.G., Lipman D., Collins F.S., Jang W., Sherry S., Feolo M.,
RA   Misquitta L., Lee E., Rotmistrovsky K., Greenhut S.F., Schaefer C.F.,
RA   Buetow K., Bonner T.I., Haussler D., Kent J., Kiekhaus M., Furey T.,
RA   Brent M., Prange C., Schreiber K., Shapiro N., Bhat N.K., Hopkins R.F.,
RA   Hsie F., Driscoll T., Soares M.B., Casavant T.L., Scheetz T.E.,
RA   Brown-stein M.J., Usdin T.B., Toshiyuki S., Carninci P., Piao Y.,
RA   Dudekula D.B., Ko M.S., Kawakami K., Suzuki Y., Sugano S., Gruber C.E.,
RA   Smith M.R., Simmons B., Moore T., Waterman R., Johnson S.L., Ruan Y.,
RA   Wei C.L., Mathavan S., Gunaratne P.H., Wu J., Garcia A.M., Hulyk S.W.,
RA   Fuh E., Yuan Y., Sneed A., Kowis C., Hodgson A., Muzny D.M., McPherson J.,
RA   Gibbs R.A., Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S.,
RA   Sanchez A., Whiting M., Madari A., Young A.C., Wetherby K.D., Granite S.J.,
RA   Kwong P.N., Brinkley C.P., Pearson R.L., Bouffard G.G., Blakesly R.W.,
RA   Green E.D., Dickson M.C., Rodriguez A.C., Grimwood J., Schmutz J.,
RA   Myers R.M., Butterfield Y.S., Griffith M., Griffith O.L., Krzywinski M.I.,
RA   Liao N., Morin R., Morrin R., Palmquist D., Petrescu A.S., Skalska U.,
RA   Smailus D.E., Stott J.M., Schnerch A., Schein J.E., Jones S.J., Holt R.A.,
RA   Baross A., Marra M.A., Clifton S., Makowski K.A., Bosak S., Malek J.;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-332 (ISOFORM SOMATIC), AND PARTIAL PROTEIN
RP   SEQUENCE.
RX   PubMed=2841312;
RA   Bernstein K.E., Martin B.M., Bernstein E.A., Linton J., Striker L.,
RA   Striker G.;
RT   "The isolation of angiotensin-converting enzyme cDNA.";
RL   J. Biol. Chem. 263:11021-11024(1988).
RN   [5]
RP   PROTEIN SEQUENCE OF 35-54.
RC   TISSUE=Kidney;
RX   PubMed=2835538; DOI=10.1038/ki.1988.48;
RA   Bernstein K.E., Martin B.M., Striker L., Striker G.;
RT   "Partial protein sequence of mouse and bovine kidney angiotensin converting
RT   enzyme.";
RL   Kidney Int. 33:652-655(1988).
RN   [6]
RP   ALTERNATIVE PROMOTER USAGE, FUNCTION (ISOFORM TESTIS-SPECIFIC), AND TISSUE
RP   SPECIFICITY (ISOFORM TESTIS-SPECIFIC).
RX   PubMed=1651914;
RA   Langford K.G., Shai S.Y., Howard T.E., Kovac M.J., Overbeek P.A.,
RA   Bernstein K.E.;
RT   "Transgenic mice demonstrate a testis-specific promoter for angiotensin-
RT   converting enzyme.";
RL   J. Biol. Chem. 266:15559-15562(1991).
RN   [7]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=7753170; DOI=10.1038/375146a0;
RA   Krege J.H., John S.W., Langenbach L.L., Hodgin J.B., Hagaman J.R.,
RA   Bachman E.S., Jennette J.C., O'Brien D.A., Smithies O.;
RT   "Male-female differences in fertility and blood pressure in ACE-deficient
RT   mice.";
RL   Nature 375:146-148(1995).
RN   [8]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=8642790;
RA   Esther C.R. Jr., Howard T.E., Marino E.M., Goddard J.M., Capecchi M.R.,
RA   Bernstein K.E.;
RT   "Mice lacking angiotensin-converting enzyme have low blood pressure, renal
RT   pathology, and reduced male fertility.";
RL   Lab. Invest. 74:953-965(1996).
RN   [9]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-151.
RC   STRAIN=C57BL/6J; TISSUE=Plasma;
RX   PubMed=16944957; DOI=10.1021/pr060186m;
RA   Ghesquiere B., Van Damme J., Martens L., Vandekerckhove J., Gevaert K.;
RT   "Proteome-wide characterization of N-glycosylation events by diagonal
RT   chromatography.";
RL   J. Proteome Res. 5:2438-2447(2006).
RN   [10]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=9231832; DOI=10.1161/01.hyp.30.1.128;
RA   Tian B., Meng Q.C., Chen Y.F., Krege J.H., Smithies O., Oparil S.;
RT   "Blood pressures and cardiovascular homeostasis in mice having reduced or
RT   absent angiotensin-converting enzyme gene function.";
RL   Hypertension 30:128-133(1997).
RN   [11]
RP   FUNCTION (ISOFORM TESTIS-SPECIFIC), AND DISRUPTION PHENOTYPE.
RX   PubMed=9664078; DOI=10.1172/jci3545;
RA   Ramaraj P., Kessler S.P., Colmenares C., Sen G.C.;
RT   "Selective restoration of male fertility in mice lacking angiotensin-
RT   converting enzymes by sperm-specific expression of the testicular
RT   isozyme.";
RL   J. Clin. Invest. 102:371-378(1998).
RN   [12]
RP   FUNCTION (ISOFORM TESTIS-SPECIFIC), AND DISRUPTION PHENOTYPE.
RX   PubMed=9482924; DOI=10.1073/pnas.95.5.2552;
RA   Hagaman J.R., Moyer J.S., Bachman E.S., Sibony M., Magyar P.L., Welch J.E.,
RA   Smithies O., Krege J.H., O'Brien D.A.;
RT   "Angiotensin-converting enzyme and male fertility.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:2552-2557(1998).
RN   [13]
RP   FUNCTION (ISOFORM TESTIS-SPECIFIC), AND DISRUPTION PHENOTYPE.
RX   PubMed=10831599; DOI=10.1074/jbc.m004006200;
RA   Kessler S.P., Rowe T.M., Gomos J.B., Kessler P.M., Sen G.C.;
RT   "Physiological non-equivalence of the two isoforms of angiotensin-
RT   converting enzyme.";
RL   J. Biol. Chem. 275:26259-26264(2000).
RN   [14]
RP   FUNCTION, CATALYTIC ACTIVITY, AND ACTIVITY REGULATION.
RX   PubMed=11303049;
RA   Junot C., Gonzales M.F., Ezan E., Cotton J., Vazeux G., Michaud A.,
RA   Azizi M., Vassiliou S., Yiotakis A., Corvol P., Dive V.;
RT   "RXP 407, a selective inhibitor of the N-domain of angiotensin I-converting
RT   enzyme, blocks in vivo the degradation of hemoregulatory peptide acetyl-
RT   Ser-Asp-Lys-Pro with no effect on angiotensin I hydrolysis.";
RL   J. Pharmacol. Exp. Ther. 297:606-611(2001).
RN   [15]
RP   FUNCTION (ISOFORM TESTIS-SPECIFIC), AND DISRUPTION PHENOTYPE.
RX   PubMed=11723129; DOI=10.1074/jbc.m109474200;
RA   Kessler S.P., Gomos J.B., Scheidemantel T.S., Rowe T.M., Smith H.L.,
RA   Sen G.C.;
RT   "The germinal isozyme of angiotensin-converting enzyme can substitute for
RT   the somatic isozyme in maintaining normal renal structure and functions.";
RL   J. Biol. Chem. 277:4271-4276(2002).
RN   [16]
RP   FUNCTION (ISOFORM TESTIS-SPECIFIC), AND DISRUPTION PHENOTYPE.
RX   PubMed=12777443; DOI=10.1074/jbc.m3023472000;
RA   Kessler S.P., deS Senanayake P., Scheidemantel T.S., Gomos J.B., Rowe T.M.,
RA   Sen G.C.;
RT   "Maintenance of normal blood pressure and renal functions are independent
RT   effects of angiotensin-converting enzyme.";
RL   J. Biol. Chem. 278:21105-21112(2003).
RN   [17]
RP   FUNCTION, AND MUTAGENESIS OF 395-HIS--HIS-399.
RX   PubMed=14757757; DOI=10.1074/jbc.m400149200;
RA   Fuchs S., Xiao H.D., Cole J.M., Adams J.W., Frenzel K., Michaud A.,
RA   Zhao H., Keshelava G., Capecchi M.R., Corvol P., Bernstein K.E.;
RT   "Role of the N-terminal catalytic domain of angiotensin-converting enzyme
RT   investigated by targeted inactivation in mice.";
RL   J. Biol. Chem. 279:15946-15953(2004).
RN   [18]
RP   TISSUE SPECIFICITY.
RX   PubMed=16154999; DOI=10.1074/jbc.m508460200;
RA   Hemming M.L., Selkoe D.J.;
RT   "Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme
RT   (ACE) and elevated by an ACE inhibitor.";
RL   J. Biol. Chem. 280:37644-37650(2005).
RN   [19]
RP   FUNCTION (ISOFORM TESTIS-SPECIFIC), ACTIVITY REGULATION (ISOFORM
RP   TESTIS-SPECIFIC), ACTIVE SITE, AND MUTAGENESIS OF HIS-993; GLU-994 AND
RP   HIS-997.
RX   PubMed=15665832; DOI=10.1038/nm1179;
RA   Kondoh G., Tojo H., Nakatani Y., Komazawa N., Murata C., Yamagata K.,
RA   Maeda Y., Kinoshita T., Okabe M., Taguchi R., Takeda J.;
RT   "Angiotensin-converting enzyme is a GPI-anchored protein releasing factor
RT   crucial for fertilization.";
RL   Nat. Med. 11:160-166(2005).
RN   [20]
RP   FUNCTION (ISOFORM TESTIS-SPECIFIC), DISRUPTION PHENOTYPE, AND MUTAGENESIS
RP   OF 413-LYS--LYS-417 (ISOFORM TESTIS-SPECIFIC).
RX   PubMed=16270063; DOI=10.1038/nm1105-1140;
RA   Fuchs S., Frenzel K., Hubert C., Lyng R., Muller L., Michaud A., Xiao H.D.,
RA   Adams J.W., Capecchi M.R., Corvol P., Shur B.D., Bernstein K.E.;
RT   "Male fertility is dependent on dipeptidase activity of testis ACE.";
RL   Nat. Med. 11:1140-1142(2005).
RN   [21]
RP   MUTAGENESIS OF 413-LYS--LYS-417 (ISOFORM TESTIS-SPECIFIC).
RX   PubMed=17634445; DOI=10.1095/biolreprod.107.060004;
RA   Deguchi E., Tani T., Watanabe H., Yamada S., Kondoh G.;
RT   "Dipeptidase-inactivated tACE action in vivo: selective inhibition of
RT   sperm-zona pellucida binding in the mouse.";
RL   Biol. Reprod. 77:794-802(2007).
RN   [22]
RP   FUNCTION (ISOFORM TESTIS-SPECIFIC).
RX   PubMed=17135368; DOI=10.1096/fj.06-6678com;
RA   Kessler S.P., Senanayake P.D., Gaughan C., Sen G.C.;
RT   "Vascular expression of germinal ACE fails to maintain normal blood
RT   pressure in ACE-/- mice.";
RL   FASEB J. 21:156-166(2007).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brain cortex;
RX   PubMed=17114649; DOI=10.1074/mcp.M600046-MCP200;
RA   Munton R.P., Tweedie-Cullen R., Livingstone-Zatchej M., Weinandy F.,
RA   Waidelich M., Longo D., Gehrig P., Potthast F., Rutishauser D., Gerrits B.,
RA   Panse C., Schlapbach R., Mansuy I.M.;
RT   "Qualitative and quantitative analyses of protein phosphorylation in naive
RT   and stimulated mouse synaptosomal preparations.";
RL   Mol. Cell. Proteomics 6:283-293(2007).
RN   [24]
RP   DISRUPTION PHENOTYPE.
RX   PubMed=18443281; DOI=10.1073/pnas.0802690105;
RA   Jayasooriya A.P., Mathai M.L., Walker L.L., Begg D.P., Denton D.A.,
RA   Cameron-Smith D., Egan G.F., McKinley M.J., Rodger P.D., Sinclair A.J.,
RA   Wark J.D., Weisinger H.S., Jois M., Weisinger R.S.;
RT   "Mice lacking angiotensin-converting enzyme have increased energy
RT   expenditure, with reduced fat mass and improved glucose clearance.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:6531-6536(2008).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1305, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brain, Brown adipose tissue, Heart, Kidney, Liver, Lung,
RC   Pancreas, Spleen, and Testis;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and expression.";
RL   Cell 143:1174-1189(2010).
RN   [26]
RP   SUBCELLULAR LOCATION.
RX   PubMed=23535237; DOI=10.1152/ajpcell.00364.2012;
RA   Xiao L., Haack K.K., Zucker I.H.;
RT   "Angiotensin II regulates ACE and ACE2 in neurons through p38 mitogen-
RT   activated protein kinase and extracellular signal-regulated kinase 1/2
RT   signaling.";
RL   Am. J. Physiol. 304:C1073-C1079(2013).
RN   [27]
RP   FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND TISSUE SPECIFICITY.
RX   PubMed=35201898; DOI=10.1126/science.abl5130;
RA   Trieu B.H., Remmers B.C., Toddes C., Brandner D.D., Lefevre E.M.,
RA   Kocharian A., Retzlaff C.L., Dick R.M., Mashal M.A., Gauthier E.A., Xie W.,
RA   Zhang Y., More S.S., Rothwell P.E.;
RT   "Angiotensin-converting enzyme gates brain circuit-specific plasticity via
RT   an endogenous opioid.";
RL   Science 2022:eabl5130-eabl5130(2022).
CC   -!- FUNCTION: Dipeptidyl carboxypeptidase that removes dipeptides from the
CC       C-terminus of a variety of circulating hormones, such as angiotensin I,
CC       bradykinin or enkephalins, thereby playing a key role in the regulation
CC       of blood pressure, electrolyte homeostasis or synaptic plasticity
CC       (PubMed:7753170, PubMed:8642790, PubMed:9231832, PubMed:11723129,
CC       PubMed:12777443, PubMed:14757757, PubMed:16270063, PubMed:35201898).
CC       Composed of two similar catalytic domains, each possessing a functional
CC       active site, with different selectivity for substrates
CC       (PubMed:11303049). Plays a major role in the angiotensin-renin system
CC       that regulates blood pressure and sodium retention by the kidney by
CC       converting angiotensin I to angiotensin II, resulting in an increase of
CC       the vasoconstrictor activity of angiotensin (PubMed:9231832,
CC       PubMed:11303049, PubMed:14757757). Also able to inactivate bradykinin,
CC       a potent vasodilator, and therefore enhance the blood pressure response
CC       (By similarity). Acts as a regulator of synaptic transmission by
CC       mediating cleavage of neuropeptide hormones, such as substance P,
CC       neurotensin or enkephalins (By similarity). Catalyzes degradation of
CC       different enkephalin neuropeptides (Met-enkephalin, Leu-enkephalin,
CC       Met-enkephalin-Arg-Phe and possibly Met-enkephalin-Arg-Gly-Leu)
CC       (PubMed:35201898). Acts as a regulator of synaptic plasticity in the
CC       nucleus accumbens of the brain by mediating cleavage of Met-enkephalin-
CC       Arg-Phe, a strong ligand of Mu-type opioid receptor OPRM1, into Met-
CC       enkephalin (PubMed:35201898). Met-enkephalin-Arg-Phe cleavage by ACE
CC       decreases activation of OPRM1, leading to long-term synaptic
CC       potentiation of glutamate release (PubMed:35201898). Also acts as a
CC       regulator of hematopoietic stem cell differentiation by mediating
CC       degradation of hemoregulatory peptide N-acetyl-SDKP (AcSDKP)
CC       (PubMed:11303049). Acts as a regulator of cannabinoid signaling pathway
CC       by mediating degradation of hemopressin, an antagonist peptide of the
CC       cannabinoid receptor CNR1 (By similarity). Involved in amyloid-beta
CC       metabolism by catalyzing degradation of Amyloid-beta protein 40 and
CC       Amyloid-beta protein 42 peptides, thereby preventing plaque formation
CC       (By similarity). Catalyzes cleavage of cholecystokinin (maturation of
CC       Cholecystokinin-8 and Cholecystokinin-5) and Gonadoliberin-1 (both
CC       maturation and degradation) hormones (By similarity). Degradation of
CC       hemoregulatory peptide N-acetyl-SDKP (AcSDKP) and amyloid-beta proteins
CC       is mediated by the N-terminal catalytic domain, while angiotensin I and
CC       cholecystokinin cleavage is mediated by the C-terminal catalytic region
CC       (PubMed:11303049). {ECO:0000250|UniProtKB:P12821,
CC       ECO:0000269|PubMed:11303049, ECO:0000269|PubMed:11723129,
CC       ECO:0000269|PubMed:12777443, ECO:0000269|PubMed:14757757,
CC       ECO:0000269|PubMed:16270063, ECO:0000269|PubMed:35201898,
CC       ECO:0000269|PubMed:7753170, ECO:0000269|PubMed:8642790,
CC       ECO:0000269|PubMed:9231832}.
CC   -!- FUNCTION: [Angiotensin-converting enzyme, soluble form]: Soluble form
CC       that is released in blood plasma and other body fluids following
CC       proteolytic cleavage in the juxtamembrane stalk region.
CC       {ECO:0000250|UniProtKB:P12821}.
CC   -!- FUNCTION: [Isoform Testis-specific]: Isoform produced by alternative
CC       promoter usage that is specifically expressed in spermatocytes and
CC       adult testis, and which is required for male fertility (PubMed:1651914,
CC       PubMed:9482924). In contrast to somatic isoforms, only contains one
CC       catalytic domain (PubMed:16270063). Acts as a dipeptidyl
CC       carboxypeptidase that removes dipeptides from the C-terminus of
CC       substrates (PubMed:16270063). The identity of substrates that are
CC       needed for male fertility is unknown (PubMed:16270063). Isoform Testis-
CC       specific and isoform Somatic have distinct activities and cannot
CC       completely compensate for the loss of the other when expressed in
CC       somatic tissues or testis (PubMed:9664078, PubMed:10831599,
CC       PubMed:11723129, PubMed:12777443, PubMed:16270063). May also have a
CC       glycosidase activity which releases GPI-anchored proteins from the
CC       membrane by cleaving the mannose linkage in the GPI moiety
CC       (PubMed:15665832). The GPIase activity was reported to be essential for
CC       the egg-binding ability of the sperm (PubMed:15665832). This activity
CC       is however unclear and has been challenged by other groups, suggesting
CC       that it may be indirect (PubMed:16270063).
CC       {ECO:0000269|PubMed:10831599, ECO:0000269|PubMed:11723129,
CC       ECO:0000269|PubMed:12777443, ECO:0000269|PubMed:15665832,
CC       ECO:0000269|PubMed:16270063, ECO:0000269|PubMed:1651914,
CC       ECO:0000269|PubMed:9482924, ECO:0000269|PubMed:9664078}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Release of a C-terminal dipeptide, oligopeptide-|-Xaa-Yaa,
CC         when Xaa is not Pro, and Yaa is neither Asp nor Glu. Thus, conversion
CC         of angiotensin I to angiotensin II, with increase in vasoconstrictor
CC         activity, but no action on angiotensin II.; EC=3.4.15.1;
CC         Evidence={ECO:0000269|PubMed:11303049};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=angiotensin I + H2O = angiotensin II + L-histidyl-L-leucine;
CC         Xref=Rhea:RHEA:63560, ChEBI:CHEBI:15377, ChEBI:CHEBI:58506,
CC         ChEBI:CHEBI:147350, ChEBI:CHEBI:147392; EC=3.4.15.1;
CC         Evidence={ECO:0000269|PubMed:11303049};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:63561;
CC         Evidence={ECO:0000269|PubMed:11303049};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=bradykinin + H2O = bradykinin(1-7) + L-Phe-L-Arg;
CC         Xref=Rhea:RHEA:71451, ChEBI:CHEBI:15377, ChEBI:CHEBI:132988,
CC         ChEBI:CHEBI:133147, ChEBI:CHEBI:147352;
CC         Evidence={ECO:0000250|UniProtKB:P12821};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:71452;
CC         Evidence={ECO:0000250|UniProtKB:P12821};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + substance P = L-Leu-L-Met-NH2 + substance P(1-9);
CC         Xref=Rhea:RHEA:71459, ChEBI:CHEBI:15377, ChEBI:CHEBI:190692,
CC         ChEBI:CHEBI:190693, ChEBI:CHEBI:190700;
CC         Evidence={ECO:0000250|UniProtKB:P12821};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:71460;
CC         Evidence={ECO:0000250|UniProtKB:P12821};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + substance P = Gly-L-Leu-L-Met-NH2 + substance P(1-8);
CC         Xref=Rhea:RHEA:71463, ChEBI:CHEBI:15377, ChEBI:CHEBI:190692,
CC         ChEBI:CHEBI:190694, ChEBI:CHEBI:190699;
CC         Evidence={ECO:0000250|UniProtKB:P12821};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:71464;
CC         Evidence={ECO:0000250|UniProtKB:P12821};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + substance P = L-Phe-L-Phe-Gly-L-Leu-L-Met-NH2 +
CC         substance P(1-6); Xref=Rhea:RHEA:71471, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:190692, ChEBI:CHEBI:190696, ChEBI:CHEBI:190697;
CC         Evidence={ECO:0000250|UniProtKB:P12821};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:71472;
CC         Evidence={ECO:0000250|UniProtKB:P12821};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + neurotensin = L-isoleucyl-L-leucine + neurotensin(1-11);
CC         Xref=Rhea:RHEA:71475, ChEBI:CHEBI:15377, ChEBI:CHEBI:147362,
CC         ChEBI:CHEBI:190704, ChEBI:CHEBI:190706;
CC         Evidence={ECO:0000250|UniProtKB:P12821};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:71476;
CC         Evidence={ECO:0000250|UniProtKB:P12821};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=goralatide + H2O = L-lysyl-L-proline + N-acetyl-L-seryl-L-
CC         aspartate; Xref=Rhea:RHEA:71455, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:190701, ChEBI:CHEBI:190702, ChEBI:CHEBI:190703;
CC         Evidence={ECO:0000269|PubMed:11303049};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:71456;
CC         Evidence={ECO:0000269|PubMed:11303049};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + Met-enkephalin = L-phenylalanyl-L-methionine + L-
CC         tyrosylglycylglycine; Xref=Rhea:RHEA:71483, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:189868, ChEBI:CHEBI:190708, ChEBI:CHEBI:190709;
CC         Evidence={ECO:0000250|UniProtKB:P12821};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:71484;
CC         Evidence={ECO:0000250|UniProtKB:P12821};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + Leu-enkephalin = L-phenylalanyl-L-leucine + L-
CC         tyrosylglycylglycine; Xref=Rhea:RHEA:71487, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:190689, ChEBI:CHEBI:190708, ChEBI:CHEBI:190710;
CC         Evidence={ECO:0000250|UniProtKB:P12821};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:71488;
CC         Evidence={ECO:0000250|UniProtKB:P12821};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + Met-enkephalin-Arg-Phe = L-arginyl-L-phenylalanine +
CC         Met-enkephalin; Xref=Rhea:RHEA:70675, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:189868, ChEBI:CHEBI:189869, ChEBI:CHEBI:189870;
CC         Evidence={ECO:0000269|PubMed:35201898};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:70676;
CC         Evidence={ECO:0000269|PubMed:35201898};
CC   -!- CATALYTIC ACTIVITY: [Isoform Testis-specific]:
CC       Reaction=Release of a C-terminal dipeptide, oligopeptide-|-Xaa-Yaa,
CC         when Xaa is not Pro, and Yaa is neither Asp nor Glu. Thus, conversion
CC         of angiotensin I to angiotensin II, with increase in vasoconstrictor
CC         activity, but no action on angiotensin II.; EC=3.4.15.1;
CC         Evidence={ECO:0000269|PubMed:16270063};
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000250|UniProtKB:P12821};
CC       Note=Binds 2 Zn(2+) ions per subunit. {ECO:0000250|UniProtKB:P12821};
CC   -!- COFACTOR: [Isoform Testis-specific]:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000250|UniProtKB:P12821};
CC       Note=Isoform Testis-specific only binds 1 Zn(2+) ion per subunit.
CC       {ECO:0000250|UniProtKB:P12821};
CC   -!- COFACTOR:
CC       Name=chloride; Xref=ChEBI:CHEBI:17996;
CC         Evidence={ECO:0000250|UniProtKB:P12821};
CC       Note=Binds 3 chloride ions per subunit. {ECO:0000250|UniProtKB:P12821};
CC   -!- COFACTOR: [Isoform Testis-specific]:
CC       Name=chloride; Xref=ChEBI:CHEBI:17996;
CC         Evidence={ECO:0000250|UniProtKB:P12821};
CC   -!- ACTIVITY REGULATION: The dipeptidyl carboxypeptidase activity is
CC       specifically inhibited by lisinopril, captopril and enalaprilat
CC       (PubMed:15665832, PubMed:35201898). The N-terminal catalytic domain,
CC       but not the C-terminal catalytic domain, is specifically inhibited by
CC       the phosphinic peptide RXP 407 (PubMed:11303049).
CC       {ECO:0000269|PubMed:11303049, ECO:0000269|PubMed:15665832,
CC       ECO:0000269|PubMed:35201898}.
CC   -!- ACTIVITY REGULATION: [Isoform Testis-specific]: The putative GPIase
CC       activity is nearly insensitive to captopril.
CC       {ECO:0000269|PubMed:15665832}.
CC   -!- SUBUNIT: Monomer and homodimer; homodimerizes following binding to an
CC       inhibitor (By similarity). Interacts with calmodulin (CALM1, CALM2 or
CC       CALM3); interaction takes place in the cytoplasmic region and regulates
CC       phosphorylation and proteolytic cleavage (By similarity).
CC       {ECO:0000250|UniProtKB:P12821, ECO:0000250|UniProtKB:P12822}.
CC   -!- SUBCELLULAR LOCATION: [Isoform Somatic]: Cell membrane
CC       {ECO:0000269|PubMed:23535237}; Single-pass type I membrane protein
CC       {ECO:0000255}. Cytoplasm {ECO:0000269|PubMed:23535237}. Note=Detected
CC       in both cell membrane and cytoplasm in neurons.
CC       {ECO:0000269|PubMed:23535237}.
CC   -!- SUBCELLULAR LOCATION: [Angiotensin-converting enzyme, soluble form]:
CC       Secreted {ECO:0000250|UniProtKB:P12821}.
CC   -!- SUBCELLULAR LOCATION: [Isoform Testis-specific]: Cell membrane
CC       {ECO:0000250|UniProtKB:P12821}; Single-pass type I membrane protein
CC       {ECO:0000255}. Secreted {ECO:0000250|UniProtKB:P12821}. Note=The
CC       testis-specific isoform can be cleaved before the transmembrane region,
CC       releasing a soluble form. {ECO:0000250|UniProtKB:P12821}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage; Named isoforms=2;
CC       Name=Somatic; Synonyms=sACE {ECO:0000303|PubMed:16270063};
CC         IsoId=P09470-1; Sequence=Displayed;
CC       Name=Testis-specific; Synonyms=ACE-T, tACE
CC       {ECO:0000303|PubMed:16270063}, germinal ACE
CC       {ECO:0000303|PubMed:11723129}, gACE {ECO:0000303|PubMed:11723129};
CC         IsoId=P09470-2, P22967-1; Sequence=VSP_037638, VSP_037639;
CC   -!- TISSUE SPECIFICITY: [Isoform Somatic]: Highly expressed in kidney and
CC       lung; not expressed in the liver (PubMed:16154999). In the brain,
CC       expressed in the cerebral cortex, hippocampus, cerebellum and basal
CC       ganglia/brainstem (PubMed:16154999). Highly expressed in dopamine
CC       receptor DRD1-expressing neurons in the dorsal striatum and the nucleus
CC       accumbens of the brain (PubMed:35201898). {ECO:0000269|PubMed:16154999,
CC       ECO:0000269|PubMed:35201898}.
CC   -!- TISSUE SPECIFICITY: [Isoform Testis-specific]: Specifically expressed
CC       in spermatocytes, adult testis. {ECO:0000269|PubMed:1651914}.
CC   -!- PTM: [Angiotensin-converting enzyme, soluble form]: Produced following
CC       proteolytic cleavage by secretase enzymes that cleave the transmembrane
CC       form in the juxtamembrane stalk region upstream of the transmembrane
CC       region. Cleavage can take place at different sites of the juxtamembrane
CC       stalk region. {ECO:0000250|UniProtKB:P12821}.
CC   -!- PTM: Phosphorylated by CK2 on Ser-1305; which allows membrane retention
CC       (By similarity). Phosphorylated on tyrosine residues on its
CC       extracellular part, promoting cleavage by secretase enzymes and
CC       formation of the soluble form (Angiotensin-converting enzyme, soluble
CC       form) (By similarity). {ECO:0000250|UniProtKB:P12821,
CC       ECO:0000250|UniProtKB:P12822}.
CC   -!- DISRUPTION PHENOTYPE: Mice display low blood pressure (hypotension),
CC       elevated serum potassium, anemia, urine concentration defects and gross
CC       renal structural defects (PubMed:8642790, PubMed:9231832,
CC       PubMed:11723129, PubMed:12777443). Male mice also have reduced
CC       fertility: sperm show defects in transport within the oviducts and in
CC       binding to zonae pellucidae (PubMed:7753170, PubMed:9482924). Mice also
CC       show impaired metabolism, characterized by increased energy
CC       expenditure, reduced fat mass and improved glucose clearance
CC       (PubMed:18443281). Expression of isoform Somatic in testis in knockout
CC       mice does not restore male fertility (PubMed:10831599). In contrast,
CC       expression of isoform Testis-specific in the sperm of knockout mice
CC       only restores fertility without curing other defects (PubMed:9664078).
CC       Isoform Testis-specific can substitute for isoform Somatic for normal
CC       kidney structure but not for normal blood pressure when expressed in
CC       vascular cells of knockout mice (PubMed:11723129, PubMed:12777443,
CC       PubMed:16270063). {ECO:0000269|PubMed:10831599,
CC       ECO:0000269|PubMed:11723129, ECO:0000269|PubMed:12777443,
CC       ECO:0000269|PubMed:16270063, ECO:0000269|PubMed:18443281,
CC       ECO:0000269|PubMed:7753170, ECO:0000269|PubMed:8642790,
CC       ECO:0000269|PubMed:9231832, ECO:0000269|PubMed:9482924,
CC       ECO:0000269|PubMed:9664078}.
CC   -!- DISRUPTION PHENOTYPE: [Isoform Somatic]: Mice lacking somatic isoform
CC       display normal male fertility. {ECO:0000269|PubMed:9482924}.
CC   -!- SIMILARITY: Belongs to the peptidase M2 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; J04946; AAA37147.1; -; mRNA.
DR   EMBL; J04947; AAA37148.1; -; mRNA.
DR   EMBL; M55333; AAA37149.1; -; mRNA.
DR   EMBL; M61094; AAA37150.1; -; Genomic_DNA.
DR   EMBL; BC040404; AAH40404.1; -; mRNA.
DR   EMBL; J03940; AAA37146.1; -; mRNA.
DR   CCDS; CCDS25543.1; -. [P09470-1]
DR   CCDS; CCDS25544.1; -. [P09470-2]
DR   PIR; A34171; A34171.
DR   PIR; A35655; A35655.
DR   RefSeq; NP_033728.1; NM_009598.2. [P09470-2]
DR   RefSeq; NP_997507.1; NM_207624.5. [P09470-1]
DR   AlphaFoldDB; P09470; -.
DR   SMR; P09470; -.
DR   BioGRID; 197920; 3.
DR   STRING; 10090.ENSMUSP00000001963; -.
DR   BindingDB; P09470; -.
DR   ChEMBL; CHEMBL2994; -.
DR   MEROPS; M02.001; -.
DR   MEROPS; M02.004; -.
DR   GlyConnect; 2129; 9 N-Linked glycans (5 sites).
DR   GlyGen; P09470; 14 sites, 9 N-linked glycans (5 sites).
DR   iPTMnet; P09470; -.
DR   PhosphoSitePlus; P09470; -.
DR   jPOST; P09470; -.
DR   MaxQB; P09470; -.
DR   PaxDb; P09470; -.
DR   PeptideAtlas; P09470; -.
DR   PRIDE; P09470; -.
DR   ProteomicsDB; 285580; -. [P09470-1]
DR   ProteomicsDB; 285581; -. [P09470-2]
DR   Antibodypedia; 31288; 873 antibodies from 43 providers.
DR   DNASU; 11421; -.
DR   Ensembl; ENSMUST00000001963; ENSMUSP00000001963; ENSMUSG00000020681. [P09470-1]
DR   Ensembl; ENSMUST00000001964; ENSMUSP00000001964; ENSMUSG00000020681. [P09470-2]
DR   GeneID; 11421; -.
DR   KEGG; mmu:11421; -.
DR   UCSC; uc007lxu.2; mouse. [P09470-1]
DR   UCSC; uc007lxw.2; mouse. [P09470-2]
DR   CTD; 1636; -.
DR   MGI; MGI:87874; Ace.
DR   VEuPathDB; HostDB:ENSMUSG00000020681; -.
DR   eggNOG; KOG3690; Eukaryota.
DR   GeneTree; ENSGT00940000162051; -.
DR   HOGENOM; CLU_014364_3_0_1; -.
DR   InParanoid; P09470; -.
DR   OMA; WEGWHNV; -.
DR   PhylomeDB; P09470; -.
DR   TreeFam; TF312861; -.
DR   BRENDA; 3.4.15.1; 3474.
DR   Reactome; R-MMU-2022377; Metabolism of Angiotensinogen to Angiotensins.
DR   BioGRID-ORCS; 11421; 2 hits in 73 CRISPR screens.
DR   ChiTaRS; Ace; mouse.
DR   PRO; PR:P09470; -.
DR   Proteomes; UP000000589; Chromosome 11.
DR   RNAct; P09470; protein.
DR   Bgee; ENSMUSG00000020681; Expressed in small intestine Peyer's patch and 191 other tissues.
DR   ExpressionAtlas; P09470; baseline and differential.
DR   Genevisible; P09470; MM.
DR   GO; GO:0009925; C:basal plasma membrane; ISO:MGI.
DR   GO; GO:0031526; C:brush border membrane; ISO:MGI.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005768; C:endosome; ISO:MGI.
DR   GO; GO:0009897; C:external side of plasma membrane; ISO:MGI.
DR   GO; GO:0070062; C:extracellular exosome; ISO:MGI.
DR   GO; GO:0005615; C:extracellular space; ISS:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005887; C:integral component of plasma membrane; ISS:UniProtKB.
DR   GO; GO:0005764; C:lysosome; ISO:MGI.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0097225; C:sperm midpiece; ISO:MGI.
DR   GO; GO:0031982; C:vesicle; ISO:MGI.
DR   GO; GO:0003779; F:actin binding; ISO:MGI.
DR   GO; GO:0031711; F:bradykinin receptor binding; ISO:MGI.
DR   GO; GO:0004180; F:carboxypeptidase activity; IEA:UniProtKB-KW.
DR   GO; GO:0031404; F:chloride ion binding; ISS:UniProtKB.
DR   GO; GO:0004175; F:endopeptidase activity; ISO:MGI.
DR   GO; GO:0008238; F:exopeptidase activity; ISO:MGI.
DR   GO; GO:1901363; F:heterocyclic compound binding; ISO:MGI.
DR   GO; GO:0070573; F:metallodipeptidase activity; ISS:UniProtKB.
DR   GO; GO:0004222; F:metalloendopeptidase activity; ISS:UniProtKB.
DR   GO; GO:0008237; F:metallopeptidase activity; IDA:UniProtKB.
DR   GO; GO:0051019; F:mitogen-activated protein kinase binding; ISO:MGI.
DR   GO; GO:0031434; F:mitogen-activated protein kinase kinase binding; ISO:MGI.
DR   GO; GO:0008233; F:peptidase activity; IMP:MGI.
DR   GO; GO:0008241; F:peptidyl-dipeptidase activity; IDA:UniProtKB.
DR   GO; GO:0008240; F:tripeptidyl-peptidase activity; ISO:MGI.
DR   GO; GO:0008270; F:zinc ion binding; ISO:MGI.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0050435; P:amyloid-beta metabolic process; ISO:MGI.
DR   GO; GO:0060978; P:angiogenesis involved in coronary vascular morphogenesis; ISO:MGI.
DR   GO; GO:0002003; P:angiotensin maturation; IDA:UniProtKB.
DR   GO; GO:0031100; P:animal organ regeneration; ISO:MGI.
DR   GO; GO:0050482; P:arachidonic acid secretion; ISO:MGI.
DR   GO; GO:0010815; P:bradykinin catabolic process; ISS:UniProtKB.
DR   GO; GO:0007420; P:brain development; IEA:Ensembl.
DR   GO; GO:0071838; P:cell proliferation in bone marrow; IMP:BHF-UCL.
DR   GO; GO:1904045; P:cellular response to aldosterone; IEA:Ensembl.
DR   GO; GO:0071333; P:cellular response to glucose stimulus; IEA:Ensembl.
DR   GO; GO:0042755; P:eating behavior; ISO:MGI.
DR   GO; GO:0009792; P:embryo development ending in birth or egg hatching; ISO:MGI.
DR   GO; GO:0007565; P:female pregnancy; IEA:Ensembl.
DR   GO; GO:0060047; P:heart contraction; IMP:MGI.
DR   GO; GO:0042447; P:hormone catabolic process; IDA:UniProtKB.
DR   GO; GO:0001822; P:kidney development; IMP:UniProtKB.
DR   GO; GO:0048286; P:lung alveolus development; ISO:MGI.
DR   GO; GO:0008584; P:male gonad development; IMP:UniProtKB.
DR   GO; GO:0090281; P:negative regulation of calcium ion import; ISO:MGI.
DR   GO; GO:1903597; P:negative regulation of gap junction assembly; IMP:BHF-UCL.
DR   GO; GO:0010629; P:negative regulation of gene expression; IMP:BHF-UCL.
DR   GO; GO:0046325; P:negative regulation of glucose import; ISO:MGI.
DR   GO; GO:0032091; P:negative regulation of protein binding; IMP:BHF-UCL.
DR   GO; GO:0035814; P:negative regulation of renal sodium excretion; ISO:MGI.
DR   GO; GO:0002446; P:neutrophil mediated immunity; IMP:MGI.
DR   GO; GO:0043171; P:peptide catabolic process; ISO:MGI.
DR   GO; GO:0006518; P:peptide metabolic process; ISO:MGI.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; ISO:MGI.
DR   GO; GO:0045777; P:positive regulation of blood pressure; ISO:MGI.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; ISO:MGI.
DR   GO; GO:0050769; P:positive regulation of neurogenesis; ISO:MGI.
DR   GO; GO:2000170; P:positive regulation of peptidyl-cysteine S-nitrosylation; IMP:BHF-UCL.
DR   GO; GO:1900086; P:positive regulation of peptidyl-tyrosine autophosphorylation; IMP:BHF-UCL.
DR   GO; GO:0032092; P:positive regulation of protein binding; IMP:BHF-UCL.
DR   GO; GO:0061098; P:positive regulation of protein tyrosine kinase activity; IMP:BHF-UCL.
DR   GO; GO:0003084; P:positive regulation of systemic arterial blood pressure; IMP:MGI.
DR   GO; GO:0045907; P:positive regulation of vasoconstriction; ISO:MGI.
DR   GO; GO:0010608; P:post-transcriptional regulation of gene expression; IMP:BHF-UCL.
DR   GO; GO:0060177; P:regulation of angiotensin metabolic process; ISO:MGI.
DR   GO; GO:0008217; P:regulation of blood pressure; IDA:BHF-UCL.
DR   GO; GO:1902033; P:regulation of hematopoietic stem cell proliferation; IMP:BHF-UCL.
DR   GO; GO:0014910; P:regulation of smooth muscle cell migration; ISO:MGI.
DR   GO; GO:0048167; P:regulation of synaptic plasticity; IDA:UniProtKB.
DR   GO; GO:0003081; P:regulation of systemic arterial blood pressure by renin-angiotensin; ISO:MGI.
DR   GO; GO:0071548; P:response to dexamethasone; IEA:Ensembl.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0034616; P:response to laminar fluid shear stress; IEA:Ensembl.
DR   GO; GO:0032496; P:response to lipopolysaccharide; ISO:MGI.
DR   GO; GO:0031667; P:response to nutrient levels; IEA:Ensembl.
DR   GO; GO:0097066; P:response to thyroid hormone; IEA:Ensembl.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; IEA:Ensembl.
DR   GO; GO:0019233; P:sensory perception of pain; ISO:MGI.
DR   GO; GO:0007283; P:spermatogenesis; IMP:MGI.
DR   GO; GO:0010814; P:substance P catabolic process; ISS:UniProtKB.
DR   GO; GO:0042310; P:vasoconstriction; ISO:MGI.
DR   CDD; cd06461; M2_ACE; 2.
DR   InterPro; IPR001548; Peptidase_M2.
DR   PANTHER; PTHR10514; PTHR10514; 2.
DR   Pfam; PF01401; Peptidase_M2; 2.
DR   PRINTS; PR00791; PEPDIPTASEA.
DR   PROSITE; PS00142; ZINC_PROTEASE; 2.
PE   1: Evidence at protein level;
KW   Alternative promoter usage; Calmodulin-binding; Carboxypeptidase;
KW   Cell membrane; Cytoplasm; Direct protein sequencing; Disulfide bond;
KW   Glycoprotein; Hydrolase; Membrane; Metal-binding; Metalloprotease;
KW   Phosphoprotein; Protease; Reference proteome; Repeat; Secreted; Signal;
KW   Transmembrane; Transmembrane helix; Zinc.
FT   SIGNAL          1..34
FT                   /evidence="ECO:0000269|PubMed:2835538"
FT   CHAIN           35..1312
FT                   /note="Angiotensin-converting enzyme"
FT                   /id="PRO_0000028539"
FT   CHAIN           35..1237
FT                   /note="Angiotensin-converting enzyme, soluble form"
FT                   /evidence="ECO:0000250|UniProtKB:P12821"
FT                   /id="PRO_0000028540"
FT   TOPO_DOM        35..1264
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        1265..1281
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        1282..1312
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   REGION          35..635
FT                   /note="Peptidase M2 1"
FT   REGION          636..1237
FT                   /note="Peptidase M2 2"
FT   REGION          1220..1261
FT                   /note="Juxtamembrane stalk"
FT                   /evidence="ECO:0000250|UniProtKB:P12821"
FT   ACT_SITE        396
FT                   /note="Proton acceptor 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU10095"
FT   ACT_SITE        525
FT                   /note="Proton donor 1"
FT                   /evidence="ECO:0000250|UniProtKB:Q9BYF1"
FT   ACT_SITE        994
FT                   /note="Proton acceptor 2"
FT                   /evidence="ECO:0000305|PubMed:15665832"
FT   ACT_SITE        1123
FT                   /note="Proton donor 2"
FT                   /evidence="ECO:0000250|UniProtKB:Q9BYF1"
FT   BINDING         236
FT                   /ligand="chloride"
FT                   /ligand_id="ChEBI:CHEBI:17996"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:P12821"
FT   BINDING         395
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000250|UniProtKB:P12821"
FT   BINDING         399
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000250|UniProtKB:P12821"
FT   BINDING         423
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000250|UniProtKB:P12821"
FT   BINDING         534
FT                   /ligand="chloride"
FT                   /ligand_id="ChEBI:CHEBI:17996"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:P12821"
FT   BINDING         796
FT                   /ligand="chloride"
FT                   /ligand_id="ChEBI:CHEBI:17996"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250|UniProtKB:P12821"
FT   BINDING         834
FT                   /ligand="chloride"
FT                   /ligand_id="ChEBI:CHEBI:17996"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000250|UniProtKB:P12821"
FT   BINDING         993
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000305|PubMed:15665832"
FT   BINDING         997
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000305|PubMed:15665832"
FT   BINDING         1021
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000250|UniProtKB:P12821"
FT   BINDING         1095
FT                   /ligand="chloride"
FT                   /ligand_id="ChEBI:CHEBI:17996"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250|UniProtKB:P12821"
FT   BINDING         1099
FT                   /ligand="chloride"
FT                   /ligand_id="ChEBI:CHEBI:17996"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250|UniProtKB:P12821"
FT   BINDING         1132
FT                   /ligand="chloride"
FT                   /ligand_id="ChEBI:CHEBI:17996"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000250|UniProtKB:P12821"
FT   MOD_RES         1305
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   CARBOHYD        59
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        79
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        116
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        151
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16944957"
FT   CARBOHYD        165
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        323
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        514
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        682
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        700
FT                   /note="N-linked (GlcNAc...) (complex) asparagine"
FT                   /evidence="ECO:0000250|UniProtKB:P12821"
FT   CARBOHYD        719
FT                   /note="N-linked (GlcNAc...) (complex) asparagine"
FT                   /evidence="ECO:0000250|UniProtKB:P12821"
FT   CARBOHYD        765
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        947
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1196
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        162..170
FT                   /evidence="ECO:0000250|UniProtKB:P12821"
FT   DISULFID        762..768
FT                   /evidence="ECO:0000250|UniProtKB:P12821"
FT   DISULFID        962..980
FT                   /evidence="ECO:0000250|UniProtKB:P12821"
FT   DISULFID        1148..1160
FT                   /evidence="ECO:0000250|UniProtKB:P12821"
FT   VAR_SEQ         1..580
FT                   /note="Missing (in isoform Testis-specific)"
FT                   /evidence="ECO:0000303|PubMed:2164636"
FT                   /id="VSP_037638"
FT   VAR_SEQ         581..646
FT                   /note="GCSRPWQEVLKDLVGSDALDAKALLEYFQPVSQWLEEQNQRNGEVLGWPENQ
FT                   WRPPLPDNYPEGID -> MGQGWATPGLPSFLFLLLCCGHHLLVLSQVATDHVTANQGI
FT                   TNQATTRSQTTTHQATIDQTTQIPN (in isoform Testis-specific)"
FT                   /evidence="ECO:0000303|PubMed:2164636"
FT                   /id="VSP_037639"
FT   MUTAGEN         395..399
FT                   /note="HEMGH->KEMGK: In ACE(7/7) mutant; knockin mice have
FT                   normal blood pressure, renal function, and hematocrit.
FT                   Knockin mice show normal plasma levels of angiotensin II
FT                   but an elevation of plasma and urine peptide N-acetyl-SDKP
FT                   (AcSDKP)"
FT                   /evidence="ECO:0000269|PubMed:14757757"
FT   MUTAGEN         993
FT                   /note="H->K: Abolishes peptidase activity but no effect on
FT                   GPIase activity; when associated with K-997"
FT                   /evidence="ECO:0000269|PubMed:15665832"
FT   MUTAGEN         994
FT                   /note="E->D: Abolishes peptidase activity but no effect on
FT                   GPIase activity"
FT                   /evidence="ECO:0000269|PubMed:15665832"
FT   MUTAGEN         997
FT                   /note="H->K: Abolishes peptidase activity but no effect on
FT                   GPIase activity; when associated with K-993"
FT                   /evidence="ECO:0000269|PubMed:15665832"
FT   MUTAGEN         P09470-2:413..417
FT                   /note="HEMGH->KEMGK: Abolished dipeptidyl carboxypeptidase
FT                   activity. Knockin mice expressed in a knockout background
FT                   display defects in male fertility. They however show normal
FT                   blood pressure and kidney morphology"
FT                   /evidence="ECO:0000269|PubMed:16270063,
FT                   ECO:0000269|PubMed:17135368"
FT   CONFLICT        568
FT                   /note="A -> T (in Ref. 1; AAA37147)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   1312 AA;  150918 MW;  7DF9F5BE91762DFF CRC64;
     MGAASGQRGR WPLSPPLLML SLLVLLLQPS PAPALDPGLQ PGNFSPDEAG AQLFAESYNS
     SAEVVMFQST VASWAHDTNI TEENARRQEE AALVSQEFAE VWGKKAKELY ESIWQNFTDS
     KLRRIIGSIR TLGPANLPLA QRQQYNSLLS NMSRIYSTGK VCFPNKTATC WSLDPELTNI
     LASSRSYAKL LFAWEGWHDA VGIPLKPLYQ DFTAISNEAY RQDDFSDTGA FWRSWYESPS
     FEESLEHIYH QLEPLYLNLH AYVRRALHRR YGDKYVNLRG PIPAHLLGDM WAQSWENIYD
     MVVPFPDKPN LDVTSTMVQK GWNATHMFRV SEEFFTSLGL SPMPPEFWAE SMLEKPTDGR
     EVVCHASAWD FYNRKDFRIK QCTRVTMEQL ATVHHEMGHV QYYLQYKDLH VSLRRGANPG
     FHEAIGDVLA LSVSTPAHLH KIGLLDHVTN DIESDINYLL KMALEKIAFL PFGYLVDQWR
     WGVFSGRTPP SRYNFDWWYL RTKYQGICPP VARNETHFDA GAKFHIPNVT PYIRYFVSFV
     LQFQFHQALC KEAGHQGPLH QCDIYQSAQA GAKLKQVLQA GCSRPWQEVL KDLVGSDALD
     AKALLEYFQP VSQWLEEQNQ RNGEVLGWPE NQWRPPLPDN YPEGIDLETD EAKADRFVEE
     YDRTAQVLLN EYAEANWQYN TNITIEGSKI LLEKSTEVSN HTLKYGTRAK TFDVSNFQNS
     SIKRIIKKLQ NLDRAVLPPK ELEEYNQILL DMETTYSLSN ICYTNGTCMP LEPDLTNMMA
     TSRKYEELLW AWKSWRDKVG RAILPFFPKY VEFSNKIAKL NGYTDAGDSW RSLYESDNLE
     QDLEKLYQEL QPLYLNLHAY VRRSLHRHYG SEYINLDGPI PAHLLGNMWA QTWSNIYDLV
     APFPSAPNID ATEAMIKQGW TPRRIFKEAD NFFTSLGLLP VPPEFWNKSM LEKPTDGREV
     VCHPSAWDFY NGKDFRIKQC TSVNMEDLVI AHHEMGHIQY FMQYKDLPVT FREGANPGFH
     EAIGDIMALS VSTPKHLYSL NLLSTEGSGY EYDINFLMKM ALDKIAFIPF SYLIDQWRWR
     VFDGSITKEN YNQEWWSLRL KYQGLCPPVP RSQGDFDPGS KFHVPANVPY VRYFVSFIIQ
     FQFHEALCRA AGHTGPLHKC DIYQSKEAGK LLADAMKLGY SKPWPEAMKL ITGQPNMSAS
     AMMNYFKPLT EWLVTENRRH GETLGWPEYN WAPNTARAEG STAESNRVNF LGLYLEPQQA
     RVGQWVLLFL GVALLVATVG LAHRLYNIRN HHSLRRPHRG PQFGSEVELR HS
//
ID   ARBK2_HUMAN             Reviewed;         688 AA.
AC   P35626; Q9UGW9;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 2.
DT   03-AUG-2022, entry version 204.
DE   RecName: Full=Beta-adrenergic receptor kinase 2;
DE            Short=Beta-ARK-2;
DE            EC=2.7.11.15 {ECO:0000250|UniProtKB:P26819};
DE   AltName: Full=G-protein-coupled receptor kinase 3 {ECO:0000312|MIM:109636};
GN   Name=GRK3 {ECO:0000312|MIM:109636}; Synonyms=ADRBK2, BARK2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   PubMed=8427589; DOI=10.1006/bbrc.1993.1072;
RA   Parruti G., Ambrosini G., Sallese M., de Blasi A.;
RT   "Molecular cloning, functional expression and mRNA analysis of human beta-
RT   adrenergic receptor kinase 2.";
RL   Biochem. Biophys. Res. Commun. 190:475-481(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M., Clamp M.,
RA   Smink L.J., Ainscough R., Almeida J.P., Babbage A.K., Bagguley C.,
RA   Bailey J., Barlow K.F., Bates K.N., Beasley O.P., Bird C.P., Blakey S.E.,
RA   Bridgeman A.M., Buck D., Burgess J., Burrill W.D., Burton J., Carder C.,
RA   Carter N.P., Chen Y., Clark G., Clegg S.M., Cobley V.E., Cole C.G.,
RA   Collier R.E., Connor R., Conroy D., Corby N.R., Coville G.J., Cox A.V.,
RA   Davis J., Dawson E., Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M.,
RA   Ellington A.G., Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S., Hunt S.E.,
RA   Jones M.C., Kershaw J., Kimberley A.M., King A., Laird G.K., Langford C.F.,
RA   Leversha M.A., Lloyd C., Lloyd D.M., Martyn I.D., Mashreghi-Mohammadi M.,
RA   Matthews L.H., Mccann O.T., Mcclay J., Mclaren S., McMurray A.A.,
RA   Milne S.A., Mortimore B.J., Odell C.N., Pavitt R., Pearce A.V., Pearson D.,
RA   Phillimore B.J.C.T., Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y.,
RA   Rogers L., Ross M.T., Scott C.E., Sehra H.K., Skuce C.D., Smalley S.,
RA   Smith M.L., Soderlund C., Spragon L., Steward C.A., Sulston J.E.,
RA   Swann R.M., Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J., Shintani A.,
RA   Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S., Roe B.A., Chen F., Chu L.,
RA   Crabtree J., Deschamps S., Do A., Do T., Dorman A., Fang F., Fu Y., Hu P.,
RA   Hua A., Kenton S., Lai H., Lao H.I., Lewis J., Lewis S., Lin S.-P., Loh P.,
RA   Malaj E., Nguyen T., Pan H., Phan S., Qi S., Qian Y., Ray L., Ren Q.,
RA   Shaull S., Sloan D., Song L., Wang Q., Wang Y., Wang Z., White J.,
RA   Willingham D., Wu H., Yao Z., Zhan M., Zhang G., Chissoe S., Murray J.,
RA   Miller N., Minx P., Fulton R., Johnson D., Bemis G., Bentley D.,
RA   Bradshaw H., Bourne S., Cordes M., Du Z., Fulton L., Goela D., Graves T.,
RA   Hawkins J., Hinds K., Kemp K., Latreille P., Layman D., Ozersky P.,
RA   Rohlfing T., Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K.,
RA   Nelson J., Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S., Budarf M.L.,
RA   McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E., Edelmann L., Kim U.J.,
RA   Shizuya H., Simon M.I., Dumanski J.P., Peyrard M., Kedra D., Seroussi E.,
RA   Fransson I., Tapia I., Bruder C.E., O'Brien K.P., Wilkinson P.,
RA   Bodenteich A., Hartman K., Hu X., Khan A.S., Lane L., Tilahun Y.,
RA   Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [3]
RP   UBIQUITINATION.
RX   PubMed=20596523; DOI=10.1371/journal.pone.0011332;
RA   Del Rincon S.V., Rogers J., Widschwendter M., Sun D., Sieburg H.B.,
RA   Spruck C.;
RT   "Development and validation of a method for profiling post-translational
RT   modification activities using protein microarrays.";
RL   PLoS ONE 5:E11332-E11332(2010).
RN   [4]
RP   VARIANTS [LARGE SCALE ANALYSIS] SER-50; SER-60 AND LYS-104.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Specifically phosphorylates the agonist-occupied form of the
CC       beta-adrenergic and closely related receptors.
CC       {ECO:0000250|UniProtKB:P26819}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=[beta-adrenergic receptor] + ATP = [beta-adrenergic receptor]-
CC         phosphate + ADP + H(+); Xref=Rhea:RHEA:19429, Rhea:RHEA-COMP:11222,
CC         Rhea:RHEA-COMP:11223, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:43176, ChEBI:CHEBI:68546, ChEBI:CHEBI:456216;
CC         EC=2.7.11.15; Evidence={ECO:0000250|UniProtKB:P26819};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:19430;
CC         Evidence={ECO:0000250|UniProtKB:P26819};
CC   -!- SUBUNIT: Interacts with GIT1. {ECO:0000250|UniProtKB:P26819}.
CC   -!- INTERACTION:
CC       P35626; P25098: GRK2; NbExp=2; IntAct=EBI-2875868, EBI-3904795;
CC   -!- SUBCELLULAR LOCATION: Postsynapse {ECO:0000250|UniProtKB:P26819}.
CC       Presynapse {ECO:0000250|UniProtKB:P26819}.
CC   -!- PTM: Ubiquitinated. {ECO:0000269|PubMed:20596523}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. GPRK subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X69117; CAA48870.1; -; mRNA.
DR   EMBL; AL022329; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS13832.1; -.
DR   PIR; JC1469; JC1469.
DR   RefSeq; NP_005151.2; NM_005160.3.
DR   AlphaFoldDB; P35626; -.
DR   SMR; P35626; -.
DR   BioGRID; 106666; 13.
DR   IntAct; P35626; 6.
DR   STRING; 9606.ENSP00000317578; -.
DR   BindingDB; P35626; -.
DR   ChEMBL; CHEMBL1075166; -.
DR   DrugBank; DB00171; ATP.
DR   GuidetoPHARMACOLOGY; 1467; -.
DR   GlyConnect; 1034; 1 N-Linked glycan (1 site).
DR   GlyGen; P35626; 1 site, 1 N-linked glycan (1 site).
DR   iPTMnet; P35626; -.
DR   PhosphoSitePlus; P35626; -.
DR   BioMuta; GRK3; -.
DR   DMDM; 116241253; -.
DR   EPD; P35626; -.
DR   jPOST; P35626; -.
DR   MassIVE; P35626; -.
DR   MaxQB; P35626; -.
DR   PaxDb; P35626; -.
DR   PeptideAtlas; P35626; -.
DR   PRIDE; P35626; -.
DR   ProteomicsDB; 55118; -.
DR   Antibodypedia; 234; 431 antibodies from 34 providers.
DR   DNASU; 157; -.
DR   Ensembl; ENST00000324198.11; ENSP00000317578.4; ENSG00000100077.16.
DR   GeneID; 157; -.
DR   KEGG; hsa:157; -.
DR   MANE-Select; ENST00000324198.11; ENSP00000317578.4; NM_005160.4; NP_005151.2.
DR   UCSC; uc003abx.5; human.
DR   CTD; 157; -.
DR   DisGeNET; 157; -.
DR   GeneCards; GRK3; -.
DR   HGNC; HGNC:290; GRK3.
DR   HPA; ENSG00000100077; Tissue enhanced (adipose).
DR   MIM; 109636; gene.
DR   neXtProt; NX_P35626; -.
DR   OpenTargets; ENSG00000100077; -.
DR   PharmGKB; PA41; -.
DR   VEuPathDB; HostDB:ENSG00000100077; -.
DR   eggNOG; KOG0986; Eukaryota.
DR   GeneTree; ENSGT00940000157699; -.
DR   InParanoid; P35626; -.
DR   OMA; KHFSLTI; -.
DR   OrthoDB; 1083437at2759; -.
DR   PhylomeDB; P35626; -.
DR   TreeFam; TF313940; -.
DR   BRENDA; 2.7.11.15; 2681.
DR   PathwayCommons; P35626; -.
DR   Reactome; R-HSA-418555; G alpha (s) signalling events.
DR   Reactome; R-HSA-8856825; Cargo recognition for clathrin-mediated endocytosis.
DR   SignaLink; P35626; -.
DR   SIGNOR; P35626; -.
DR   BioGRID-ORCS; 157; 11 hits in 1109 CRISPR screens.
DR   ChiTaRS; GRK3; human.
DR   GeneWiki; Beta_adrenergic_receptor_kinase-2; -.
DR   GenomeRNAi; 157; -.
DR   Pharos; P35626; Tchem.
DR   PRO; PR:P35626; -.
DR   Proteomes; UP000005640; Chromosome 22.
DR   RNAct; P35626; protein.
DR   Bgee; ENSG00000100077; Expressed in Brodmann (1909) area 23 and 184 other tissues.
DR   ExpressionAtlas; P35626; baseline and differential.
DR   Genevisible; P35626; HS.
DR   GO; GO:0070161; C:anchoring junction; IEA:UniProtKB-KW.
DR   GO; GO:0042995; C:cell projection; IEA:UniProtKB-KW.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0098794; C:postsynapse; IEA:UniProtKB-SubCell.
DR   GO; GO:0098793; C:presynapse; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0047696; F:beta-adrenergic receptor kinase activity; TAS:Reactome.
DR   GO; GO:0001664; F:G protein-coupled receptor binding; IBA:GO_Central.
DR   GO; GO:0004703; F:G protein-coupled receptor kinase activity; IBA:GO_Central.
DR   GO; GO:0004672; F:protein kinase activity; IBA:GO_Central.
DR   GO; GO:0002029; P:desensitization of G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0006468; P:protein phosphorylation; IBA:GO_Central.
DR   GO; GO:0031623; P:receptor internalization; IDA:UniProtKB.
DR   GO; GO:0009966; P:regulation of signal transduction; IBA:GO_Central.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   Gene3D; 1.10.167.10; -; 1.
DR   Gene3D; 2.30.29.30; -; 1.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR000239; GPCR_kinase.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR016137; RGS.
DR   InterPro; IPR036305; RGS_sf.
DR   InterPro; IPR044926; RGS_subdomain_2.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00169; PH; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00615; RGS; 1.
DR   PRINTS; PR00717; GPCRKINASE.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00315; RGS; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF48097; SSF48097; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS50132; RGS; 1.
PE   1: Evidence at protein level;
KW   ATP-binding; Cell projection; Kinase; Nucleotide-binding;
KW   Reference proteome; Serine/threonine-protein kinase; Synapse; Transferase;
KW   Ubl conjugation.
FT   CHAIN           1..688
FT                   /note="Beta-adrenergic receptor kinase 2"
FT                   /id="PRO_0000085632"
FT   DOMAIN          54..175
FT                   /note="RGS"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00171"
FT   DOMAIN          191..453
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          454..521
FT                   /note="AGC-kinase C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00618"
FT   DOMAIN          558..652
FT                   /note="PH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00145"
FT   REGION          1..190
FT                   /note="N-terminal"
FT   REGION          669..688
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        317
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         197..205
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         220
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   VARIANT         50
FT                   /note="R -> S (in dbSNP:rs55700971)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040380"
FT   VARIANT         60
FT                   /note="N -> S (in dbSNP:rs55740593)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040381"
FT   VARIANT         104
FT                   /note="R -> K (in a lung bronchoalveolar carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040382"
FT   VARIANT         409
FT                   /note="V -> M (in dbSNP:rs2272859)"
FT                   /id="VAR_028005"
FT   CONFLICT        308
FT                   /note="M -> V (in Ref. 1; CAA48870)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   688 AA;  79710 MW;  50844236A01C1423 CRC64;
     MADLEAVLAD VSYLMAMEKS KATPAARASK RIVLPEPSIR SVMQKYLAER NEITFDKIFN
     QKIGFLLFKD FCLNEINEAV PQVKFYEEIK EYEKLDNEED RLCRSRQIYD AYIMKELLSC
     SHPFSKQAVE HVQSHLSKKQ VTSTLFQPYI EEICESLRGD IFQKFMESDK FTRFCQWKNV
     ELNIHLTMNE FSVHRIIGRG GFGEVYGCRK ADTGKMYAMK CLDKKRIKMK QGETLALNER
     IMLSLVSTGD CPFIVCMTYA FHTPDKLCFI LDLMNGGDLH YHLSQHGVFS EKEMRFYATE
     IILGLEHMHN RFVVYRDLKP ANILLDEHGH ARISDLGLAC DFSKKKPHAS VGTHGYMAPE
     VLQKGTAYDS SADWFSLGCM LFKLLRGHSP FRQHKTKDKH EIDRMTLTVN VELPDTFSPE
     LKSLLEGLLQ RDVSKRLGCH GGGSQEVKEH SFFKGVDWQH VYLQKYPPPL IPPRGEVNAA
     DAFDIGSFDE EDTKGIKLLD CDQELYKNFP LVISERWQQE VTETVYEAVN ADTDKIEARK
     RAKNKQLGHE EDYALGKDCI MHGYMLKLGN PFLTQWQRRY FYLFPNRLEW RGEGESRQNL
     LTMEQILSVE ETQIKDKKCI LFRIKGGKQF VLQCESDPEF VQWKKELNET FKEAQRLLRR
     APKFLNKPRS GTVELPKPSL CHRNSNGL
//
